Prema Maria Mertz

Array ( [id] => 16805912 [patent_doc_number] => 20210128465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => PHARMACEUTICAL COMPOSITIONS OF IL-2 [patent_app_type] => utility [patent_app_number] => 16/926881 [patent_app_country] => US [patent_app_date] => 2020-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16926881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16620038 [patent_doc_number] => 20210038691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE-RELATED OR INFLAMMATORY [patent_app_type] => utility [patent_app_number] => 16/925983 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20386604 [patent_doc_number] => 12486321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Agents that interfere with IL-1BETA receptor signalling [patent_app_type] => utility [patent_app_number] => 17/759154 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 14 [patent_no_of_words] => 9821 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822688 [patent_doc_number] => 20210137981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/906781 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16906781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17968250 [patent_doc_number] => 11485764 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-01 [patent_title] => Production of recombinant lubricin [patent_app_type] => utility [patent_app_number] => 16/904978 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 24 [patent_no_of_words] => 10502 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18216465 [patent_doc_number] => 11591387 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Compounds and methods targeting interleukin-19 [patent_app_type] => utility [patent_app_number] => 16/903731 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13340 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16903731 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895462 [patent_doc_number] => 20220305124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => Photolysis to Unlock Caged Protein Therapeutics [patent_app_type] => utility [patent_app_number] => 17/616917 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17944408 [patent_doc_number] => 20220331425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => TREATMENT OF CANCERS WITH GM-CSF ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/616307 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999458 [patent_doc_number] => 11078249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same [patent_app_type] => utility [patent_app_number] => 16/886177 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 86 [patent_no_of_words] => 19503 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16886177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18478289 [patent_doc_number] => 11692019 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-04 [patent_title] => Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same [patent_app_type] => utility [patent_app_number] => 16/886184 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 86 [patent_no_of_words] => 19529 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16886184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297766 [patent_doc_number] => 20200283489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/880624 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297767 [patent_doc_number] => 20200283490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/880606 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18028949 [patent_doc_number] => 11512122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => IL-7-FC-fusion proteins [patent_app_type] => utility [patent_app_number] => 16/875878 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 25531 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16875878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711908 [patent_doc_number] => 20210079055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 [patent_app_type] => utility [patent_app_number] => 15/930057 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733330 [patent_doc_number] => 20220218789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections [patent_app_type] => utility [patent_app_number] => 17/594940 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421930 [patent_doc_number] => 20200347128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => MODULATING THE EFFECTS OF GAMMA-C-CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA ASSOCIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/863914 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727849 [patent_doc_number] => 20210094996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => Targeted Immunotolerance [patent_app_type] => utility [patent_app_number] => 16/857340 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328427 [patent_doc_number] => 20200299393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/858488 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18354024 [patent_doc_number] => 11642409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-09 [patent_title] => Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof [patent_app_type] => utility [patent_app_number] => 16/857999 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 78 [patent_no_of_words] => 78408 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720431 [patent_doc_number] => 20220213151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF DISTENTABLE TISSUES [patent_app_type] => utility [patent_app_number] => 17/602193 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602193 [rel_patent_id] =>[rel_patent_doc_number] =>)